Alexion
Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
Rankings by
National Ranking224th
in United States Regional Ranking249th
in North America and Caribbean Global Ranking623rd
worldwide